These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33146841)

  • 1. Diagnostic performance of MRI for HCC according to contrast agent type: a systematic review and meta-analysis.
    Kim DW; Choi SH; Kim SY; Byun JH; Lee SS; Park SH; Kim KW
    Hepatol Int; 2020 Dec; 14(6):1009-1022. PubMed ID: 33146841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic performance of MRI for residual or recurrent hepatocellular carcinoma after locoregional treatment according to contrast agent type: a systematic review and meta‑analysis.
    Zhou S; Wang S; Xiang J; Han Z; Wang W; Zhang S; Opara NC; Ju S; Cui Y; Wang YC
    Abdom Radiol (NY); 2024 Feb; 49(2):471-483. PubMed ID: 38200213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnetic Resonance Imaging With Extracellular Contrast Detects Hepatocellular Carcinoma With Greater Accuracy Than With Gadoxetic Acid or Computed Tomography.
    Min JH; Kim JM; Kim YK; Cha DI; Kang TW; Kim H; Choi GS; Choi SY; Ahn S
    Clin Gastroenterol Hepatol; 2020 Aug; 18(9):2091-2100.e7. PubMed ID: 31843599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diagnostic performance of contrast-enhanced CT versus extracellular contrast agent-enhanced MRI in detecting hepatocellular carcinoma: direct comparison and a meta-analysis.
    Chen X; Li M; Guo R; Liu W; Li J; Zong X; Chen Q; Wang J
    Abdom Radiol (NY); 2022 Jun; 47(6):2057-2070. PubMed ID: 35312822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraindividual Comparison of MRIs with Extracellular and Hepatobiliary Contrast Agents for the Noninvasive Diagnosis of Hepatocellular Carcinoma Using the Korean Liver Cancer Association-National Cancer Center 2022 Criteria.
    Yoon JK; Han DH; Lee S; Choi JY; Choi GH; Kim DY; Kim MJ
    Cancer Res Treat; 2023 Jul; 55(3):939-947. PubMed ID: 36791769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs.
    Paisant A; Vilgrain V; Riou J; Oberti F; Sutter O; Laurent V; Rodes A; Guiu B; Cassinotto C; Trillaud H; Bricault I; Michalak S; Bruno O; Ronot M; Aubé C
    J Hepatol; 2020 May; 72(5):937-945. PubMed ID: 31870951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis of recurrent HCC: intraindividual comparison of gadoxetic acid MRI and extracellular contrast-enhanced MRI.
    Yim JH; Kim YK; Min JH; Lee J; Kang TW; Lee SJ
    Abdom Radiol (NY); 2019 Jul; 44(7):2366-2376. PubMed ID: 30847566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extracellular contrast-enhanced MRI with diffusion-weighted imaging for HCC diagnosis: prospective comparison with gadoxetic acid using LI-RADS.
    Cha DI; Choi GS; Kim YK; Kim JM; Kang TW; Song KD; Ahn SH
    Eur Radiol; 2020 Jul; 30(7):3723-3734. PubMed ID: 32128620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraindividual Comparison of Hepatocellular Carcinoma Washout between MRIs with Hepatobiliary and Extracellular Contrast Agents.
    Kim YY; Kim YK; Min JH; Cha DI; Kim JM; Choi GS; Ahn S
    Korean J Radiol; 2021 May; 22(5):725-734. PubMed ID: 33660458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective Intraindividual Comparison of Magnetic Resonance Imaging With Gadoxetic Acid and Extracellular Contrast for Diagnosis of Hepatocellular Carcinomas Using the Liver Imaging Reporting and Data System.
    Min JH; Kim JM; Kim YK; Kang TW; Lee SJ; Choi GS; Choi SY; Ahn S
    Hepatology; 2018 Dec; 68(6):2254-2266. PubMed ID: 30070365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EASL versus LI-RADS: Intra-individual comparison of MRI with extracellular contrast and gadoxetic acid for diagnosis of small HCC.
    Min JH; Kim JM; Kim YK; Kim H; Cha DI; Kang TW; Choi GS; Choi SY; Ahn S
    Liver Int; 2021 Dec; 41(12):2986-2996. PubMed ID: 34242468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions.
    Min JH; Kim JM; Kim YK; Kim H; Choi GS; Kang TW; Cha D; Hwang JA; Ko SE; Ahn S
    Eur Radiol; 2022 Feb; 32(2):912-922. PubMed ID: 34345947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective comparison of EASL 2018 and LI-RADS 2018 for the noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.
    Lee S; Kim MJ; Kim SS; Shin H; Kim DY; Choi JY; Park MS; Mitchell DG
    Hepatol Int; 2020 Jan; 14(1):70-79. PubMed ID: 31802388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic performance of MRI using extracellular contrast agents versus gadoxetic acid for hepatocellular carcinoma: A systematic review and meta-analysis.
    Feng Z; Zhao H; Guan S; Wang W; Rong P
    Liver Int; 2021 May; 41(5):1117-1128. PubMed ID: 33647177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.
    Lee S; Kim SS; Chang DR; Kim H; Kim MJ
    Clin Mol Hepatol; 2020 Jul; 26(3):340-351. PubMed ID: 32492765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic performance of CT versus MRI Liver Imaging Reporting and Data System category 5 for hepatocellular carcinoma: a systematic review and meta-analysis of comparative studies.
    Kim YY; Lee S; Shin J; Son WJ; Roh YH; Hwang JA; Lee JE
    Eur Radiol; 2022 Oct; 32(10):6723-6729. PubMed ID: 35849177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraindividual comparison of prognostic imaging features of HCCs between MRIs with extracellular and hepatobiliary contrast agents.
    Yoon JK; Han DH; Lee S; Choi JY; Choi GH; Kim DY; Kim MJ
    Liver Int; 2024 Oct; 44(10):2847-2857. PubMed ID: 39105495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LI-RADS Major Features on MRI for Diagnosing Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Shin J; Lee S; Yoon JK; Chung YE; Choi JY; Park MS
    J Magn Reson Imaging; 2021 Aug; 54(2):518-525. PubMed ID: 33638582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing capsule in hepatocellular carcinoma: intra-individual comparison between CT and MRI with extracellular contrast agent.
    Cannella R; Ronot M; Sartoris R; Cauchy F; Hobeika C; Beaufrere A; Trapani L; Paradis V; Bouattour M; Bonvalet F; Vilgrain V; Dioguardi Burgio M
    Diagn Interv Imaging; 2021 Dec; 102(12):735-742. PubMed ID: 34284951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic Performance of LI-RADS v2018 versus KLCA-NCC 2018 Criteria for Hepatocellular Carcinoma Using Magnetic Resonance Imaging with Hepatobiliary Agent: A Systematic Review and Meta-Analysis of Comparative Studies.
    Shin J; Lee S; Yoon JK; Son WJ; Roh YH; Chung YE; Choi JY; Park MS
    Gut Liver; 2023 May; 17(3):466-474. PubMed ID: 36317516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.